[PubMed] [CrossRef] [Google Scholar] 9

On By msisig

[PubMed] [CrossRef] [Google Scholar] 9. and specificity of 98.8%. CAY10566 Using a panel of immune sera related to additional coronaviruses, we confirm the lack of cross-reactivity to additional coronaviruses in SARS-CoV-2 sVNT and PRNT90, except for cross-reactivity to SARS-CoV-1 in sVNT. KEYWORDS: SARS coronavirus 2, COVID-19, serology, neutralization, seroepidemiology, human being, animal, SARS-CoV-2, antibody, canine, cat, hamster, surrogate computer virus neutralization INTRODUCTION Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in 2019 to cause a pandemic. For seroepidemiology studies and in outbreak investigations, it is important to detect antibody reactions in humans and animals to ascertain evidence of recent illness with SARS-CoV-2. Antibody assays that are transferable across varieties are desired because SARS-CoV-2 infects household pets and additional farmed animals (e.g., mink) (1,C3), for monitoring antibody reactions in experimental animal models (4), and in studies to identify the natural animal reservoir of SARS-CoV-2. Enzyme-linked immunosorbent assays (ELISAs) of the computer virus spike receptor binding website (RBD), which has the fewest cross-reactive epitopes in common with additional coronaviruses, or of the whole spike protein or nucleoprotein are widely used for detection of antibody in humans (5,C7). Computer virus neutralization assays are used for confirming positive results but require handling live computer virus in biosafety level 3 (BSL-3) containment facilities or the use CAY10566 of a pseudotyped computer virus (6). ELISAs utilized for detection of antibody in additional animal species require assays to be reoptimized with the CAY10566 relevant species-specific anti-Ig conjugate for detecting immunoglobulins of each species. For some species, relevant anti-Ig reagents may not be available. The currently available common alternative has been the use of CAY10566 computer virus neutralization test (VNTs), which usually involve handling live computer virus in BSL-3 containment. A surrogate VNT (sVNT) that can be done in BSL-2 containment has recently been reported (8). It is an assay that relies on competitive inhibition of the connection of ACE-2 receptor coated on an ELISA plate with horseradish peroxidase (HRP)-labeled computer virus spike receptor binding website. We used a panel of sera from individuals or animals with real-time PCR (RT-PCR)-confirmed SARS-CoV-2 illness and corresponding settings to evaluate this sVNT in comparison to the platinum standard 90% plaque reduction neutralization checks (PRNT90). MATERIALS AND METHODS Sera. Sera from individuals with RT-PCR-confirmed SARS-CoV-2 illness (value? LSM16 between percent inhibition in the surrogate computer virus neutralization test (sVNT) and (A) 90% plaque reduction neutralization test (PRNT90) titer or (B) spike RBD ELISA IgG optical denseness of 205 sera from humans with results confirmed by RT-PCR. (A) Correlation between PRNT90 and percent inhibition in the sVNT. We fitted a linear log regression model between percent inhibition in the sVNT (sVNT%) and log-transformed PRNT90 titers as follows: value?